The patient of Faux et al. (1973) was a 3-year-old boy wiith recurrent respiratory infections and otitis media from the age of 6 months. There is no mention of dyspnoea or of radiological appearances. The pa(tient described by Moroz et al. (1971) was a woman aged 30 with a history of repeated tonsillitis since childhood. No description is given of chest x-rav picture or mediastinal glands. In this case the abnormal IgA was alzo detected in two svmptomless relatives and culture of the patient's tonsillar lvmphocytes showed that they were able to synthesize light chains as well as alpha-heavy chains, suggesting a familial defect of assembly. This patient's urine contained both alpha-chains and Bence Jones proteins. In the Dutch girl only a trace of alpha-chains was detected and in the boy nothing was found on seventy-fold urinary concentrations.
In heavy-chain disease generally the concentration and molecular weight of the abnormal proteins vary considerablv, hence the irregular urinary excretion. Bence Jones proteinuria is usually minimal and in some cases no lieht chains seem to be synthesized (Seligmann et al., 1968) . In both the intestinal and the pulmonary forms of alpha-chain disease the abnormal immunoglobulin is devoid of light chains and the heavy chains show varying degrees of deletion in the aminoacid sequence, concerning mainly the Fd portion (Frangione et al., 1971) . None of the pulmonary cases including our own showed any evidence of lymphoma. Stoop et al.'s girl developed a pharyangeal paragranuloma in which, however, no IgA-secreting cells could be shown. The disease seems to ibe fairly benign since three patients are alive and our patient died at 78 without any evidence of malignancy at necropsy. He had a heavy proteinuria, but unfortunately the urine was not studied since the diagnosis was not suspected during life. In the serum the IgA consisted entirely of abnormal alpha-chains, suggesting that the synthesis of normal IgA molecules was inhibited. This alpha-chain differs from those in previous cases in that it seems to have an antibody activity detected by immunofluorescence and directed against a constituent of rat mitochondria. It is usually considered that both heavy-chain and light-chain N-terminals are needed for antibody activity, but there is another precedent in a Bence Jones protein reported bv Os',erman et al. (1964) which apparently gave a cvtoplasmic fluorescence on several tissues. Possibly this antibody activity represents a cross reaction with a bacterial or viral antigen. Further studies on the nature of the anitigen are in progress. So far it is known that the patient's serum showed no high titres of antibodies to rubella, measles, and herpes tvpe 1 viruses, and absorption with cardiolipin (Venereal Disease Research Laboratory antigen), streptolysin 0, and staphylolysin failed to inhibit the mitochondrial fluorescence seen on rat tissues. Introduction A combination of rifampicin 900 mg and isoniazid 750 mg given twice weekly seems as effective in the treatment of *tuberculosis as rifampicin 600 mg and isoniazid 450 mg given daily . A disadvantage of the twiceweekly regimen, however, is that side effects occur, which seem to be related to the intermittent use of rifampicin (Blajchman et al., 1970; Poole et al., 1971) . To investigate the reasons for these adverse reactions in intermittent therapy we 'studied the cases of a group of patients followed up af£ter their discharge from hospital and of another group who had been referred for immunological investigation to the Centre Departemental de Transfusion Sanguine of Paris (C.D.T.S.). This paper reports our findings. Though these confirmed those of others, there were certain differences which we think have an important bearing on the prevention of side effects to rifampicin.
Patients and Methods
The cases of two groups of patients, a total of 291, were studied. The first group comprised 200 hospital patients. Of these 50 had received rifampicin 900 mg and isoniazid 750 mg twice weekly from the start of their treatment in 1969, and the remaining 150 had begun this intermittent regimen after an initial three-month period of daily rifampicin. The patients came from four differen-t hospitals and all had completed their treatment when the study was made. The results of treatment have been reported . The second group comprised 91 patients whose serum had been sen-t to the C.D.T.S. either for systematic immunological studies or because of side effects.
Serum rifampicin levels had been determined routinely in 30 of the 200 hospital patients after six months' treatment. Serum rifampicin levels had also been determined in another two patients who had presented with adverse reactions. Determinations were made by observing the inhibitory effect of serum on a culture of Sarcina lutea I.P. 5,345 in a gelose nutrient three, six, and eight hours after a single 900-mg dose of rifampicin.
An antiglobulin test in the presence of the drug and a lymphocy,te -transformation test had been carried out in the immunological study of an adequate number of cases.
ANTIGLOBULIN TEST
The same technique was used for all sera in the antiglobulin test and three reactions were observed in each serum. For the first, one drlop of patient's serum (either pure or diluted in saline) was mixed with one drop of rifampicin 60 mg/100 ml saline, one drop of compatible normal human red cells in 5% suspension in saline, and one drop of fresh compatible serum. For the second (serum control) the patient's serum, compatible normal human red cells, and fresh compatible human serum were mixed and saline was substi-tuted for rifampicin. For the third (rifampicin control) the rifampicin solution, compatible normal human red cells, and fresh compatible human serum were mixed. The serum of a patient receiving no rifampicin treatment was substituted for the patient's serum. The ,three mixtures were incubated at 37'C for two hours, and, after washing, the antiglobulin test was then carried out. The antiglobulin used (Institut Pasteur, Paris, Lot 8,661) had been chosen for its high anticomplementary activity.
The rifampicin solution used in the tests was itaken from a stock solution prepared by dissolving one 300-mg rifampicin capsule in 500 ml of saline. The drug dissolved completely within 48 hours. (This solution can be kept for six months without appreciable loss of activity if stored at 4'C and sheltered from light.) For a positive reaction the strength of the rifampicin solution had to be at least 1-10 mg/100 ml saline, and the stronger the solution the more clear-cut was the reaction.
If enzyme-treated red blood cells are used in the test the reaction is stronger, with a tiitre two dilutions higher, but about 2 /o of sera agglutinate enzyme-treated red cells at 37GC and the antiglobulin must be checked against such red cells. We -therefore preferred to use untreated normal red blood cells. With normal red cells incuba-tion at 370C must be for two hours for an optimum reaction, but with enzymetreated cells the incubation period is one hour. The reaction is usuallv negative with the an.ti-IgG, anti-IgA, and anti-IgM antiglobulins (Sors et al., 1972 
Results
Eight cases of immunological intolerance had been found, of which five were among the group of 200 hospital patients who had been on intermittent rifampicin treatment-an incidence of 2-5%. Of the three cases of immunological intolerance among ithe group of 91 patients referred to ithe C.D.T.S. one had been on intermittent treatment and two had been on continuous rifampicin therapy (600 mg daily). Side effects had recurred in these two patients when treatment was restarted.
In every case the adverse reactions had occurred after several weeks of rifampicin therapy-mostly after a period of between three and 15 months. In one patient (case 1, table I) rifampicin had been given intermittently (900 mg twice weekly) from the start. Side effects occurred at the end of the third month. In five patients (cases 2-6) 600 mg rifampicin daily for the first three months had been followed by an intermittent regimen of 900 mg twice weekly. Side effects occurred after six to 18 months. One of these patients (case 3) had again had adverse reactions eight weeks after rifampicin treatment was resumed with a smalled twiceweekly dose of 300 mg. The two patients (cases 7 and 8) who had developed adverse reaotions while on continuous therapy had again had side effects when a 600-mg dose of rifampicin was given 30 and 75 days respectively after cessation of treatment.
The symptoms of adverse reaction in each case had showed from one to four hours after a dose of rifampicin. Recovery had occurred spontaneously within 10 hours. The symptoms were mainly those of a chill with fever and associated myalgia. Renal failure developed in three cases, haemolysis in one, and purpura in another (table I) . Adverse reactions when they recurred were always of the same type. Four patients respectively had ithe following number of reaotions: five (case 2), seven (case 3), four (case 4), and fifteen (case 1). The remaining four patients had one reaction each. (Decroix and Pujet, 1973 Reactions to rifampicin seem to be related to the concentration of the drug in the blood. This may be affected by dosage or by the rate of metabolism. The incidence of side effects in relation to dosage in several series of cases are shown in table V. That drugs must first be bound to plasma proteins to become antigenic (Landsteiner et al., 1945 ) is generally accepted. Probably high serum concentrations of rifampicin, which is poorly soluble, favour its binding to certain blood proteins. Binding to substances such as albumin and lipoproteins has been shown in vitro (Aoyagi, 1972; Boman, 1972; Nillson, 1972) .
Therefore it seems that to prevent reaotions to rifampicin the dosage must be adjusted to the pa-tient's ability to metabolize it. Doses smaller than 900 mg should be given to those in whom the blood concentration rises abnormally. With a daily dosage of 600 mg we saw few reactions, and on routine testing of 63 patients 15 days after the end of 12 months' treatment with this dosage we found no antibodies. Patients who have adverse reactions to rifampicin are almost always those who are taking the drug intermittently (usually twice, but sometimes once or thrice weekly) or those who were on a continuous regimen and -then resume taking the drug after an infterval (cases 7 and 8) (Hasse et al., 1971; Fergusson, 1971) . In one patient (case 2) the antibody titre notably decreased after a 900-mg dose of rifampicin (table IV) and then rose within 24 hours (Sors et al., 1972 (table VI) . Positive results will be found, however, whether or not the patient shows any clinical evidence of red cell haemolysis. This has been seen in cases of intolerance to para-aminosalicylic acid (Dausset and Bergerot-Blondel, 1961) and ,to a contrast medium (Kleinknecht et al., 1974 (Sors et al., 1972) . In a case of thrombocytopenic purpura the antibody was IgG (Blajchman et al., 1970) . In all seven of our intolerant patients with a positive response to the antiglobulin test the antigenic site for the drug was at the junction of the rifampicin nucleus and the side chain . There is therefore no cross reaction between rifampicin and rifamycin SV, and a patient initolerant to rifampicin may be given rifamycin SV without fear of side effects and with a resulting decrease in rifampicin antibody titre (Decroix et al., 1973 (Cooper and Brown, 1971) , if the reaction stops at C3. This accounts for adverse reaotions to rifampicin in the form of haemolytic anaemia or thrombocytopenic purpura. In most cases, however, the reaotion shows as pyrexia, chills, myalgia, digestive disorders, and sometimes anuria. But it is not known whether these symptoms are associated with the fixation on the red cells of complexes that aotivate the complement and release degradation products or with the fixation of complexes on other cells-for example, mastocytes or vascular endothelial cells. Thi.s problem has been discussed (Decroix et al., 1973; Kleinknecht et al., 1972) and is worth investigating further.
